By: Ryan Cross, Andrew Dunn
Evolution is very powerful and very slow. A new startup thinks it can harness its might — without the millennia of waiting around.
Andrew Dunn is a Biopharma Correspondent at Endpoints, a leading source of biopharmaceutical news. With a focus on the biopharma industry, Andrew covers topics such as drug development, healthcare investments, FDA approvals, and industry trends. His work has been featured in various publications, including Quartz, Business Insider, Bloomberg News, and Yahoo Finance, showcasing his expertise in the field of biopharmaceuticals.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Andrew Dunn's coverage primarily focuses on the healthcare and pharmaceutical industry, particularly on biotech, pharmaceutical companies, and research & development. He also covers business and finance aspects related to these sectors.
Given his high percentage of press releases in his coverage attributes, Andrew might be more inclined towards news directly from companies within the healthcare and pharmaceutical industries. Therefore, he may be interested in pitches that provide exclusive insights into new drug developments, breakthrough technologies or significant funding announcements within these sectors.
As Andrew often writes about CEOs and investments in the industry, experts who can offer unique perspectives on leadership strategies within biotech/pharmaceutical companies or trends in R&D investment could grab his attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .